National Heart and Lung Institute, Imperial College London, and Royal Brompton Hospital, Airways Disease Section, London, UK.
Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville.
Mayo Clin Proc. 2021 Sep;96(9):2448-2463. doi: 10.1016/j.mayocp.2021.03.016. Epub 2021 Jun 26.
For more than 50 years, small airways disease has been considered a key feature of chronic obstructive pulmonary disease (COPD) and a major cause of airway obstruction. Both preventable and treatable, small airways disease has important clinical consequences if left unchecked. Small airways disease is associated with poor spirometry results, increased lung hyperinflation, and poor health status, making the small airways an important treatment target in COPD. The early detection of small airways disease remains the key barrier; if detected early, treatments designed to target small airways may help reduce symptoms and allow patients to maintain their activities. Studies are needed to evaluate the possible role of new drugs and novel drug formulations, inhalers, and inhalation devices for treating small airways disease. These developments will help to improve our management of small airways disease in patients with COPD.
50 多年来,小气道疾病一直被认为是慢性阻塞性肺疾病(COPD)的一个关键特征,也是气道阻塞的主要原因。小气道疾病既可预防也可治疗,如果不加以控制,会产生重要的临床后果。小气道疾病与较差的肺量计结果、肺过度充气增加和健康状况较差有关,这使得小气道成为 COPD 的一个重要治疗靶点。小气道疾病的早期检测仍然是关键障碍;如果早期发现,旨在针对小气道的治疗可能有助于减轻症状并使患者能够维持其活动能力。需要研究新药物和新型药物制剂、吸入器和吸入装置治疗小气道疾病的可能作用。这些进展将有助于改善我们对 COPD 患者小气道疾病的管理。